Hepatitis C: efficacy and safety in real life

Liver International

Volumn 37, Issue , 2017, Pages 26-32

  Flisiak, Robert ^a   Pogorzelska, Joanna ^a   Flisiak Jackiewicz, Marta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

direct acting antivirals; hepatitis C; real world experience

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SOFOSBUVIR; BMS-790052; IMIDAZOLE DERIVATIVE; SIMEPREVIR;

ANTIVIRAL THERAPY; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER CELL CARCINOMA; MIXED INFECTION; REVIEW; SUSTAINED VIROLOGIC RESPONSE; CHRONIC HEPATITIS C; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER CIRRHOSIS; RISK FACTOR; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS; RIBAVIRIN; RISK FACTORS; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85007575700     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13293     Document Type: Review

References (54)

1. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593.
2. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28:397–404.
3. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
4. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
5. Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs. 2013;18:461–475.
6. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)–NCT01514890. J Hepatol. 2013;59:434–441.
7. Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV—myth or foreseeable future? Liver Int. 2014;34:6–11.
8. Jaroszewicz J, Flisiak-Jackiewicz M, Lebensztejn D, Flisiak R. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opin Investig Drugs. 2015;24:1229–1239.
9. Keating GM. Ledipasvir/sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015;75:675–685.
10. Curry M, Modi AA, Pungpapong S, et al. Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-experienced cirrhotic genotype 1 patients with chronic hepatitis C: a comparative analysis of Gilead sponsored trials with 4 real-world cohorts. J Hepatol. 2016;64(Suppl. 2):S797.
11. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir±ribavirin vs. ombitasvir/paritaprevir/ritonavir+ dasabuvir±ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 2016;44:400–410.
12. Rodrigues J, Tato-Marinho R, Mota-Filipe H, et al. Evidence of impressive real world SVR from the Portuguese ledipasvir/sofosbuvir and Sofosbuvir Universal Coverage Program to eradicate (eliminate) hepatitis C. J Hepatol. 2016;64(Suppl. 2):S224.
13. Afdhal N, Bacon B, Curry M, et al. No effect of proton pump inhibitor (PPI) use on SVR with ledipasvir/sofosbuvir (LDV/SOF): real world data from 2034 genotype 1 patients in the Trio network. J Hepatol. 2016;64(Suppl. 2):S222.
14. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64:405–14.
15. Younossi ZM, Park H, Gordon SC, et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care. 2016;22:SP205-11.
16. Buggisch P, Boker K, Gunther R, et al. Ledipasvir/sofosbuvir treatment for 8 weeks in treatment-naīve HCV genotype 1 infected patients under real life conditions: data from the German Hepatitis C-Registry. J Hepatol. 2016;64(Suppl. 2):S810.
17. Crespo J, Fenandez I, Cabezas J, et al. Effectiveness and safety of sofosbuvir/ledipasvir treatment for monoinfected genotype 1 HCV patients in real-life clinical practice: results from Spanish hepa-C cohort. J Hepatol. 2016;64(Suppl. 2):S217-218.
18. Terrault N, Zeuzem S, DiBisceglie AM, et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. Hepatology. 2015;62:94–It is a one page abstract, so there is no last page.
19. Flisiak R, Łucejko M, Mazur W, et al. Efficacy and safety of sofosbuvir/ledipasvir±ribavirin in the real-world HARVEST study. Clin Exp Hepatol. 2016;2:80.
20. Latt NL, Gevorkyan R, Yanny BT, et al. Ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic, treatment naive patients with genotype 1 hepatitis C infection: real life experience in a community setting. J Hepatol. 2016;64(Suppl. 2):S802-803.
21. Reddy KR, Sulkowski MS, Hassan M, et al. Safety and efficacy of new DAA regimens in kidney and liver transplant recipients with hepatitis C: interval results from the HCV-target study. Hepatol. 2016;64(Suppl. 2):S783-784.
22. Colombo M. Aghemo A, Liu L, et al. Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection. J Hepatol. 2016;64(Suppl. 2):S183.
23. McCombs J, McGinnis J, Fox S, Tonnu-Mihara I. Analysis of the real world effectiveness of direct acting antivirals treatments of hepatitis C in a large population. J Hepatol. 2016;64(Suppl. 2):S217.
24. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150:419–429.
25. Wang G., Reeves JD, Terrault N, et al. Prevalence and impact of baseline resistance-associated variants on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against gt1 HCV infection: HCV-target interim analysis. J Hepatol. 2016;64(Suppl. 2):S187-188.
26. Mauss S, Buggisch P, Böker KHW, et al. Treatment outcomes for hepatitis C genotype 1 infection with direct acting antivirals: data from the German Hepatitis C-Registry. J Hepatol. 2016;64(Suppl. 2):S820.
27. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2016;This paper is still in press, so should be left in the form with doi only. doi:10.1016/j.jhep.2016.08.021.
28. Calleja J, Rincon D, Ruiz-Antoran B, et al. Effectiveness and safety of ombitasvir and paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from Spanish real world cohort. J Hepatol. 2016;64(Suppl. 2):S218-219.
29. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44:946–956.
30. Zuckerman E. Ashkenasi E, et al. Kovalev Y, The real-world Israeli experience treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin: a large multi-center cohort. J Hepatol. 2016;64(Suppl. 2):S137.
31. Hunyady B, Abonyi M, Gervain J, et al. Ombitasvir/paritaprevir/ritonavir + dasabuvir + rybaviryn (3D + RBV) treatment of hepatitis C (HCV) genotype 1 (GT1) infected patients (pts) after failure to previous first generation protease-inhibitor (PI) therapy. interim analysis. J Hepatol. 2016;64(Suppl. 2):S750.
32. Lubel JS, Pianko S, Strasser T, et al. Real world evaluation of Viekira Pak (ritonavir boosted paritaprevir, ombitasvir and dasabuvir±ribavirin) in HCV genotype 1 targeting advanced liver disease (The Revital Study). J Hepatol. 2016;64(Suppl. 2):S780.
33. McGinnis J, McCombs J, Mehta D, Fox S, Tonnu-Mihara I, Analysis of the impact of HIV co-infection on hepatitis c treatment effectiveness for patients using new direct-acting antivirals. J Hepatol. 2016;64(Suppl. 2):S219-220.
34. Dieterich D, Bacon B, Curry M, et al. Ledipasvir/sofosbuvir+/−ribavirin in patients co-infected with HCV and HIV: real-world heterogeneous population from the Trio network. J Hepatol. 2016;64(Suppl. 2):S756-757.
35. Flamm S, Bacon B, Curry M, et al. Ledipasvir/sofosbuvir+/−ribavirin in HCV post-transplant patients: real-world heterogeneous population from the Trio network. J Hepatol. 2016;64(Suppl. 2):S822-823.
36. Tronina O, Durlik M, Wawrzynowicz-Syczewska M, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir/dasabuvir +/− ribavirin regimen for recurrent genotype 1 HCV infection after liver transplantation—multicenter, real-life, AMBER-CEE study. Transplantation. 2016;100(Suppl. 5):S93, O-41.
37. Rosenblatt R, Mehta A, Wagner M, Kumar S. Baseline creatinine clearance is a predictor of worsening renal function while on HCV treatment with sofosbuvir-ledipasvir. J Hepatol. 2016;64(Suppl. 2):S819.
38. Moreno A, Vivancos MJ, Quereda C, et al. “Real life” data on DAAs use among HCV-patients with moderate to severe chronic kidney disease not on hemodialysis. J Hepatol. 2016;64(Suppl. 2):S746.
39. Anty R, Coilly A, Fougerou C, et al. Renal dysfunction in liver transplant patients treated with sofosbuvir based-regimen for HCV recurrence: results from a large French Prospective Multicentric ANRS CO23 CUPILT. J Hepatol. 2016;64(Suppl. 2):S550.
40. Gómez R, Rincón D, Hernández E, et al. Ombitasvir/paritaprevir/ritonavir plus dasabuvir are safety and efficacy for treating HCV GT1 and 4 infection in patients with severe renal impairment or end-stage renal disease: a multicenter experience. J Hepatol. 2016;64(Suppl. 2):S813.
41. Reig M, Mariño Z, Perelló C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65:719–726.
42. Buonfiglioli F, Conti F, Andreone P, et al. Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. J Hepatol. 2016;64(Suppl. 2):S215.
43. Cheung MCM, Foster GR, Irving WL, et al. Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir/daclatasvir with or without ribavirin–6 and 12 month outcomes compared to untreated patients. J Hepatol. 2016;64(Suppl. 2):S185-186.
44. Pol S. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma. J Hepatol. 2016;66:734–740.
45. Feld JJ, Maan R, Zeuzem S, et al. Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis. 2016;63:776–783.
46. Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44:856–865.
47. Qureshi K, Andres J, Regester J, et al. Real-life outcomes of 8 weeks regimen of sofosbuvir and ledipasvir without ribavirin, in non-cirrhotic treatment-naïve hepatitis C genotype 1 patients with less than 6 million IU/ml viral load. J Hepatol. 2016;64(Suppl. 2):S786.
48. Fuchs M, Forte V, Tassone D, et al. Effectiveness of ledipasvir/sofosbuvir and ombitasvir/paritaprevir/ritonavir/dasabuvir in treatment-naïve and-experienced U.S. Veterans with genotype 1 hepatitis C infection. J Hepatol. 2016;64(Suppl. 2):S797-798.
49. Aghemo A, Cologni G, Maggiolo F, et al. Safety and efficacy of directly acting antivirals in 2432 HCV patients with advanced fibrosis: an interim analysis of the Lombardia regional network for viral hepatitis. J Hepatol. 2016;64(Suppl. 2):S213.
50. Christensen S, Ingiliz P, Schewe K, et al. Relapse and treatment-ermergent ravs with DAA-based regiments in hepatitis C virus infection (HCV) mono-or-human immunodeficiency virus (HIV)-HCV Co-infected patients—a real concern in clinical practice? Results from the German hepatitis C cohort (GECCO). J Hepatol. 2016;64(Suppl. 2):S821.
51. Derbala M, Amer A, Alkaabi S, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir, with or without ribavirin, in patients with HCV genotype 4 infection—real-world experience from Qatar. J Hepatol. 2016;64(Suppl. 2):S799-800.
52. Hinrichsen H, Wedemeyer H, Christensen S, et al. Real-world safety and effectiveness of ombitasvir/paritaprevir with dasabuvir and/or ribavirin in the German hepatitis C registry. J Hepatol. 2016;64(Suppl. 2):S159.
53. Ouzan D, Penaranda G, Delasalle ChR, et al. AVDLIB 2: news direct-acting antiviral (DDA) in HCV patients with advanced liver disease. Final results of a the second multicenter prospective observational study in real life practice in France. J Hepatol. 2016;64(Suppl. 2):S400-401.
54. Teti S, Ricciardi A, Antinori A, et al. Dasabuvir and ombitasvir/paritaprevir/ritonavir with or without ribavirin in patients with HIV-HCV coinfection: real life interim analysis of an Italian multicentre compassionate use program. J Hepatol. 2016;64(Suppl. 2):S763.